

Peter Johannsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2647372/publications.pdf>

Version: 2024-02-01

75
papers

5,771
citations

109137

35
h-index

106150

65
g-index

89
all docs

89
docs citations

89
times ranked

8259
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics, 2005, 37, 806-808.	9.4	752
3	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	3.9	222
4	Cerebral Blood Flow Measurements by Magnetic Resonance Imaging Bolus Tracking: Comparison with [15O]H2O Positron Emission Tomography in Humans. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 935-940.	2.4	212
5	Positron emission tomography of cortical centers of tinnitus. Hearing Research, 1999, 134, 133-144.	0.9	211
6	Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2016, 50, 443-453.	1.2	210
7	Cerebral activation during bicycle movements in man. Experimental Brain Research, 2000, 135, 66-72.	0.7	177
8	Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Human Molecular Genetics, 2010, 19, 2228-2238.	1.4	163
9	Brain Energy Metabolism and Blood Flow Differences in Healthy Aging. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1177-1187.	2.4	145
10	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
11	Corticobasal and ataxia syndromes widen the spectrum of <i>C9ORF72</i> hexanucleotide expansion disease. Clinical Genetics, 2013, 83, 279-283.	1.0	128
12	A Reassessment of the Neuropathology of Frontotemporal Dementia Linked to Chromosome 3. Journal of Neuropathology and Experimental Neurology, 2007, 66, 884-891.	0.9	118
13	<scp>EFNS</scp> task force: the use of neuroimaging in the diagnosis of dementia. European Journal of Neurology, 2012, 19, 1487-1501.	1.7	112
14	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
15	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
16	Cerebral Metabolic Response to Low Blood Flow: Possible Role of Cytochrome Oxidase Inhibition. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1183-1196.	2.4	90
17	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
18	Frontotemporal Dementia Caused by CHMP2B Mutations. Current Alzheimer Research, 2011, 8, 246-251.	0.7	85

#	ARTICLE	IF	CITATIONS
19	Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. <i>Acta Neuropathologica</i> , 2015, 130, 511-523.	3.9	79
20	Effect of aerobic exercise on physical performance in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1207-1215.	0.4	76
21	Origin of Human Motor Readiness Field Linked to Left Middle Frontal Gyrus by MEG and PET. <i>NeuroImage</i> , 1998, 8, 214-220.	2.1	75
22	Cortical Sites of Sustained and Divided Attention in Normal Elderly Humans. <i>NeuroImage</i> , 1997, 6, 145-155.	2.1	74
23	Cortical Responses to Sustained and Divided Attention in Alzheimer's Disease. <i>NeuroImage</i> , 1999, 10, 269-281.	2.1	71
24	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	1.8	70
25	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.4	62
26	Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). <i>Experimental Gerontology</i> , 2009, 44, 579-585.	1.2	60
27	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
28	Stimulus-dependent central processing of auditory stimuli: A PET study. <i>Scandinavian Audiology</i> , 1999, 28, 161-169.	0.5	57
29	Assessing Therapeutic Efficacy in a Progressive Disease. <i>CNS Drugs</i> , 2006, 20, 311-325.	2.7	57
30	Long-Term Cholinesterase Inhibitor Treatment of Alzheimer's Disease. <i>CNS Drugs</i> , 2004, 18, 757-768.	2.7	53
31	The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1834-1841.	1.5	46
32	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
33	Activation of Human Extrageniculostriate Pathways after Damage to Area V1. <i>NeuroImage</i> , 1999, 9, 97-107.	2.1	44
34	Preserving Cognition, Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise (ADEX Trial): Rationale and Design. <i>Neuroepidemiology</i> , 2013, 41, 198-207.	1.1	44
35	Validation of the Danish Addenbrooke's Cognitive Examination as a Screening Test in a Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 361-365.	0.7	42
36	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.		39

#	ARTICLE	IF	CITATIONS
37	Cerebral functional anatomy of voluntary contractions of ankle muscles in man. <i>Journal of Physiology</i> , 2001, 535, 397-406.	1.3	35
38	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1025-1034.	1.2	33
39	Epilepsy in Down syndrome prevalence in three age groups. <i>Seizure: the Journal of the British Epilepsy Association</i> , 1996, 5, 121-125.	0.9	30
40	Cerebral blood-flow changes evoked by two levels of painful heat stimulation: A positron emission tomography study in humans. <i>European Journal of Pain</i> , 1998, 2, 95-106.	1.4	29
41	Cortical volumes and atrophy rates in FTD-3 CHMP2B mutation carriers and related non-carriers. <i>NeuroImage</i> , 2009, 45, 713-721.	2.1	28
42	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	1.5	27
43	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1119-1128.	1.2	27
44	Dementia Diagnosis, Treatment, and Care in Specialist Clinics in Two Scandinavian Countries: A Data Comparison between the Swedish Dementia Registry (SveDem) and the Danish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 229-239.	1.2	22
45	Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. <i>Human Molecular Genetics</i> , 2017, 26, ddx003.	1.4	22
46	Cortical Centres Underlying Auditory Temporal Processing in Humans: A PET Study. <i>International Journal of Audiology</i> , 2000, 39, 30-37.	0.9	21
47	Cognitive impairment in the preclinical stage of dementia in FTD-3 CHMP2B mutation carriers: a longitudinal prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 170-176.	0.9	19
48	Dementia with Impaired Temporal Glucose Metabolism in Late-Onset Metachromatic Leukodystrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 85-88.	0.7	18
49	Presymptomatic Generalized Brain Atrophy in Frontotemporal Dementia Caused by CHMP2B Mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 182-186.	0.7	17
50	Amyloid- β , Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 193.	1.7	16
51	Development of a dementia assessment quality database. <i>Aging and Mental Health</i> , 2011, 15, 40-46.	1.5	14
52	Reversal of pathology in CHMP2B-mediated frontotemporal dementia patient cells using RNA interference. <i>Journal of Gene Medicine</i> , 2012, 14, 521-529.	1.4	14
53	A Danish adaptation of the Boston Naming Test: preliminary norms for older adults and validity in mild Alzheimer's disease. <i>Clinical Neuropsychologist</i> , 2017, 31, 72-87.	1.5	14
54	Presymptomatic cerebral blood flow changes in CHMP2B mutation carriers of familial frontotemporal dementia (FTD-3), measured with MRI. <i>BMJ Open</i> , 2012, 2, e000368.	0.8	13

#	ARTICLE	IF	CITATIONS
55	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
56	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
57	The Prevalence of Dementia in Down Syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 221-225.	0.7	12
58	Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 146-151.	0.6	12
59	Usability of Cerebrospinal Fluid Biomarkers in a Tertiary Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 553-558.	0.7	11
60	Frequency and Severity of Semantic Deficits in a Consecutive Memory Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 214-223.	0.7	11
61	Inflammatory markers of CHMP2B-mediated frontotemporal dementia. <i>Journal of Neuroimmunology</i> , 2018, 324, 136-142.	1.1	10
62	Frontotemporal Dementia Linked to Chromosome 3. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 274-276.	0.7	8
63	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
64	TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3). <i>Neurobiology of Aging</i> , 2017, 59, 221.e1-221.e7.	1.5	4
65	Six generations of CHMP2B-mediated Frontotemporal Dementia: Clinical features, predictive testing, progression, and survival. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 529-540.	1.0	4
66	O5-04-06: Moderate to high-intensity physical exercise in patients with Alzheimer's disease. , 2015, 11, P324-P325.		2
67	P4-184: Shift in Cerebral PET Glucose Metabolism in Frontotemporal Dementia Linked to Chromosome 3 (FTD-3) from the Presymptomatic to Symptomatic Stage. <i>Alzheimer's and Dementia</i> , 2016, 12, P1090.	0.4	1
68	Ageing and dementia.: Edited by K. Jellinger, F. Fazekas and M. Windisch. Published by Springer-Verlag, Vienna, 1998. 406 pp. Price US\$ 159; DM. <i>Acta Psychiatrica Scandinavica</i> , 1999, 99, 82-82.	2.2	0
69	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		0
70	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0
71	O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands. , 2015, 11, P244-P245.		0
72	P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. <i>Alzheimer's and Dementia</i> , 2016, 12, P1059.	0.4	0

#	ARTICLE	IF	CITATIONS
73	[P2â€“534]: FIRST YEAR DATA FROM THE DANISH NATIONAL DEMENTIA CLINICAL QUALITY DATABASE. Alzheimer's and Dementia, 2017, 13, P846.	0.4	0
74	Middle-Aged Man Concerned about His Family History. , 2021, , 54-58.		0
75	Cortical Frontoparietal Network Dysfunction in -Frontotemporal Dementia. Frontiers in Aging Neuroscience, 2021, 13, 714220.	1.7	0